CTNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Contineum Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$7.44+0.36 (+5.08%)
Close on Oct 19, 2026
- Market cap
- $278.76M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Contineum Therapeutics has not reported a dividend
No dividend per share appears in Contineum Therapeutics's annual filings since fiscal 2022.